2Q36.3 is Associated with Prognosis for Oestrogen Receptor-Negative Breast Cancer Patients Treated with Chemotherapy (original) (raw)
Data from ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
Olle Stål
2023
View PDFchevron_right
Clinical Studies on Hormonal Status in Breast Cancer and its Impact on Quality of Life(QOL)
Kaiser Jamil
Journal of Cancer Science & Therapy, 2009
View PDFchevron_right
Treatment for Breast Cancer: Is Time Really of the Essence?
Priscilla McAuliffe
JNCI: Journal of the National Cancer Institute, 2013
View PDFchevron_right
Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts
Garnet Anderson
Breast Cancer Research, 2018
View PDFchevron_right
Figuring Molecular Relapse in Breast Cancer Medicine
Sophie Day
Figure, 2022
View PDFchevron_right
Depths of Malignancy: On the Prognosis of Breast Cancer [Letter]
Anumta Ali
International Journal of General Medicine, 2023
View PDFchevron_right
A multidisciplinary approach to breast cancer – introducing a management file for breast cancer patients
Daiana Debucean
Archives of the Balkan Medical Union, 2020
View PDFchevron_right
Tamoxifen and fenretinide in women with metastatic breast cancer
Maria Merino
Breast Cancer Research and Treatment, 1999
View PDFchevron_right
14: Women With 10 Years of Recurrence-Free Survival Following Lumpectomy and Radiation for Invasive Breast Cancer Continue to be at Risk for Subsequent Relapse
A. Niemierko
2006
View PDFchevron_right
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer
Ute-susann Albert
Geburtshilfe und Frauenheilkunde, 2013
View PDFchevron_right
Independent Factors for Poor Prognosis in Young Patients with Stage I-III Breast Cancer
Ivan Koprivčić
Acta Clinica Croatica, 2020
View PDFchevron_right
A high burden of comorbid conditions leads to decreased survival in breast cancer
Michael Idowu
Gland surgery, 2018
View PDFchevron_right
Systemic Therapy of Metastatic Breast Cancer
Carsten Rose
Acta Oncologica, 1990
View PDFchevron_right
Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer
Liana De Vecchis
2014
View PDFchevron_right
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study
E. Medico
Breast Cancer Research and Treatment, 2014
View PDFchevron_right
Challenging Clinical Scenarios: Treatment of Patients With Triple-Negative or Basal-Like Metastatic Breast Cancer
Sally Greenberg
Clinical Breast Cancer, 2010
View PDFchevron_right
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
B. Yoo
British Journal of Cancer, 2014
View PDFchevron_right
Survival in breast cancer: A population-based study in Bangalore, India
Murali Dhar
International Journal of Cancer, 1995
View PDFchevron_right
Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy
Olle Stål
JAMA network open, 2021
View PDFchevron_right
What do ratings of cancer-specific distress mean among women at high risk of breast and ovarian cancer?
Melissa Riddle
American Journal of Medical Genetics, 2002
View PDFchevron_right
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
Philippe J Chollet
British Journal of Cancer, 2002
View PDFchevron_right
Systemic treatment of early breast cancer-a biological perspective
Sally Greenberg
Journal of Surgical Oncology, 2011
View PDFchevron_right
Association between breast and thyroid cancers
Sheryl Green
Advances in Genomics and Genetics, 2014
View PDFchevron_right
Clinical and molecular aspects of breast cancer: Targets and therapies
Glauber Leitao
Biomedicine & Pharmacotherapy, 2018
View PDFchevron_right
9q31. 2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium
E. Khusnutdinova
2012
View PDFchevron_right